Playback speed
10 seconds
Pembrolizumab for PS2 Patients with Adv. NSCLC: Results of the PePS2 Trial
By
Beacon Medical Interchange
FEATURING
Jack West
By
Beacon Medical Interchange
FEATURING
Jack West
19 views
November 16, 2018
Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of ...
read more ↘ pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population.
↖ read less
read more ↘ pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population.
↖ read less
Comments 0
Login to view comments.
Click here to Login
Lung